Ildong, Shionogi deal

Shionogi granted Ildong exclusive rights to market pirfenidone in South Korea. Ildong is responsible for regulatory approval in the territory. Details were not disclosed. Shionogi has rights to pirfenidone from Marnac Inc. (Dallas, Texas) and KDL GmbH (Basel, Switzerland) in South Korea and Taiwan as well as Japan, where the company markets it as Pirespa to treat idiopathic pulmonary fibrosis (IPF). ...